Tags

Type your tag names separated by a space and hit enter

Spider venomics: implications for drug discovery.
Future Med Chem. 2014 Oct; 6(15):1699-714.FM

Abstract

Over a period of more than 300 million years, spiders have evolved complex venoms containing an extraordinary array of toxins for prey capture and defense against predators. The major components of most spider venoms are small disulfide-bridged peptides that are highly stable and resistant to proteolytic degradation. Moreover, many of these peptides have high specificity and potency toward molecular targets of therapeutic importance. This unique combination of bioactivity and stability has made spider-venom peptides valuable both as pharmacological tools and as leads for drug development. This review describes recent advances in spider-venom-based drug discovery pipelines. We discuss spider-venom-derived peptides that are currently under investigation for treatment of a diverse range of pathologies including pain, stroke and cancer.

Authors+Show Affiliations

Institute for Molecular Bioscience, University of Queensland, Queensland, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25406008

Citation

Pineda, Sandy S., et al. "Spider Venomics: Implications for Drug Discovery." Future Medicinal Chemistry, vol. 6, no. 15, 2014, pp. 1699-714.
Pineda SS, Undheim EA, Rupasinghe DB, et al. Spider venomics: implications for drug discovery. Future Med Chem. 2014;6(15):1699-714.
Pineda, S. S., Undheim, E. A., Rupasinghe, D. B., Ikonomopoulou, M. P., & King, G. F. (2014). Spider venomics: implications for drug discovery. Future Medicinal Chemistry, 6(15), 1699-714. https://doi.org/10.4155/fmc.14.103
Pineda SS, et al. Spider Venomics: Implications for Drug Discovery. Future Med Chem. 2014;6(15):1699-714. PubMed PMID: 25406008.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spider venomics: implications for drug discovery. AU - Pineda,Sandy S, AU - Undheim,Eivind A B, AU - Rupasinghe,Darshani B, AU - Ikonomopoulou,Maria P, AU - King,Glenn F, PY - 2014/11/19/entrez PY - 2014/11/19/pubmed PY - 2015/7/7/medline SP - 1699 EP - 714 JF - Future medicinal chemistry JO - Future Med Chem VL - 6 IS - 15 N2 - Over a period of more than 300 million years, spiders have evolved complex venoms containing an extraordinary array of toxins for prey capture and defense against predators. The major components of most spider venoms are small disulfide-bridged peptides that are highly stable and resistant to proteolytic degradation. Moreover, many of these peptides have high specificity and potency toward molecular targets of therapeutic importance. This unique combination of bioactivity and stability has made spider-venom peptides valuable both as pharmacological tools and as leads for drug development. This review describes recent advances in spider-venom-based drug discovery pipelines. We discuss spider-venom-derived peptides that are currently under investigation for treatment of a diverse range of pathologies including pain, stroke and cancer. SN - 1756-8927 UR - https://www.unboundmedicine.com/medline/citation/25406008/Spider_venomics:_implications_for_drug_discovery_ L2 - https://www.future-science.com/doi/full/10.4155/fmc.14.103?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -